Esqauz 0.625mg Tablet
Esqauz 0.625mg Tablet is a female sex hormone (estrogen). It is a part of female hormone replacement therapy which helps in treating estrogen deficiency symptoms like hot flushes (red and warm face) and vaginal dryness.
Esqauz 0.625mg Tablet
Basic Information
Important information about this medicine
About This Medicine
General information about this product
Esqauz 0.625mg Tablet is a female sex hormone (estrogen). It is a part of female hormone replacement therapy which helps in treating estrogen deficiency symptoms like hot flushes (red and warm face) and vaginal dryness.
Esqauz 0.625mg Tablet is a female sex hormone (estrogen). It is a part of female hormone replacement therapy which helps in treating estrogen deficiency symptoms like hot flushes (red and warm face) and vaginal dryness.
In some cases, Esqauz 0.625mg Tablet is also used to treat breast cancer and prostate cancer along with other anticancer medicines. It is to be taken at a fixed time(s) daily. The dose and duration will be decided by your doctor so that you get the right amount to control your symptoms. If you have missed a dose, take it as soon as you remember it. Do not skip any dose and finish the full course of treatment. The treatment should not be stopped abruptly without consulting your doctor as this may affect the potency of this medicine.
The most common side effects of this HRT are headaches, breast pain, irregular vaginal bleeding or spotting, abdominal cramps or bloating, nausea, vomiting, and hair loss. Some of the warning signs and symptoms that need immediate medical attention are breast lumps, unusual vaginal bleeding, dizziness and faintness, severe headaches, chest pain, shortness of breath, pains in your legs, etc.
Before taking this medicine, it is important to tell your doctor if you are taking or have recently taken any other medicines for the same disease or other diseases. Before you initiate with this HRT, you must consult the doctor if you have a history of unexplained vaginal bleeding or if you have ever had a blood clot in your legs or your lungs. If you are pregnant or breastfeeding, you should tell your doctor before taking this medicine. Your doctor may suggest you some diagnostic or laboratory tests to know the effects and side effects of this medicine on your body.
03Uses
Prevention of Post menopausal osteoporosis
Hormone replacement therapy
04How To Use
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Esqauz 0.625mg Tablet may be taken with or without food, but it is better to take it at a fixed time.
05How It Works
Esqauz 0.625mg Tablet is a mixture of estrogens (female sex hormone). In women who are undergoing or have attained menopause, it prevents symptoms such as hot flushes, night sweats and mood swings. It also prevents the bones from becoming porous and fragile (osteoporosis).
06What If You Miss A Dose?
Q: What if you forget to take Esqauz Tablet?
A: If you miss a dose of Esqauz 0.625mg Tablet, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
07Benefits
In Prevention of Post menopausal osteoporosis
Osteoporosis is a common condition that weakens bones, making them fragile and more likely to break. It often occurs in women after menopause (end of a woman’s menstrual cycles) and is known as post-menopausal osteoporosis. Esqauz 0.625mg Tablet helps to keep your bones strong and healthy and reduces the risk of osteoporosis. It also helps maintain bone density and reduces your risk of bone fracture. You should use this medicine as it is prescribed, and for as long as it is prescribed by your doctor.
08Side Effects
Nausea
Breast pain
Hair loss
Irregular vaginal bleeding
Edema (swelling)
Vaginal spotting
Vaginal itching
Depression
Leg cramps
Abdominal cramp
Vaginal burning sensation
09Safety Information
Alcohol:CAUTION
Caution is advised when consuming alcohol with Esqauz 0.625mg Tablet. Please consult your doctor.
Pregnancy:CONSULT YOUR DOCTOR
Esqauz 0.625mg Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
Breast feeding:CONSULT YOUR DOCTOR
Information regarding the use of Esqauz 0.625mg Tablet during breastfeeding is not available. Please consult your doctor.
Driving:CONSULT YOUR DOCTOR
It is not known whether Esqauz 0.625mg Tablet alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Kidney:UNSAFE
Esqauz 0.625mg Tablet is probably unsafe to use in patients with kidney disease and should be avoided. Please consult your doctor.
Liver:UNSAFE
Esqauz 0.625mg Tablet is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
10Drug Tips
You have been prescribed Esqauz 0.625mg Tablet as a part of hormone replacement therapy to relieve symptoms of menopause.
It may also be used for preventing osteoporosis in postmenopausal women who are at high risk of fractures.
Take it at the same time everyday to help you remember to take it.
Inform your doctor if you experience any unusual vaginal bleeding or spotting, abnormal vaginal discharge or vaginal discomfort while taking Esqauz 0.625mg Tablet.
It may increase the risk of breast cancer. Have regular breast examinations.
Stop taking this medicine and inform your doctor immediately if you notice unexplained swelling and pain in your limbs, shortness of breath, chest pain, or changes in vision. These could be symptoms of a blood clot in a vein.
References
Sources and references
Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. p. 501.
Conjgated estrogen. Sandwich, Kent: Pfizer Limited; 2011 [revised Aug. 2016]. [Accessed 03 Apr. 2019] (online) Available from: View
Gambacciani M, Levancini M. Hormone replacement therapy and the prevention of postmenopausal osteoporosis. Prz Menopauzalny. 2014 Sep;13(4):213-20. [Accessed 20 Feb. 2024] (online) Available from: View
Conjugated oestrogens [Package leaflet: Information for the user]. County Kildare, Republic of Ireland: Pfizer Ireland Pharmaceuticals; 2023. [Accessed 20 Feb. 2024] (online) Available from: View
